Stories
NIPER Raebareli and AstraZeneca India Partner to Enhance Clinical Trials
N
News18•14-10-2026, 17:45
NIPER Raebareli and AstraZeneca India Partner to Enhance Clinical Trials
- •The National Institute of Pharmaceutical Education and Research Raebareli and AstraZeneca India signed an MoU to strengthen clinical research capabilities in India.
- •The partnership supports the Government of India's Biopharma SHAKTI initiative to establish 1000 clinical trial sites nationwide.
- •Twenty-five clinical trial sites across emerging geographies will be adopted to build a trained workforce through targeted mentoring and capability assessments.
- •AstraZeneca India will contribute clinical development expertise and support site-readiness while the Department of Pharmaceuticals provides direction.
- •NIPER Raebareli will offer structured training and certification through its Centre of Excellence as part of this scalable national model.
Key Questions Answered
The partnership aims to strengthen India's clinical research capabilities, establish inspection-ready sites beyond metropolitan centres, and support the government's Biopharma SHAKTI initiative.
Under the partnership, 25 clinical trial sites across emerging geographies will be adopted to build a trained workforce through capability assessments, targeted mentoring, and process strengthening.
The Department of Pharmaceuticals will provide direction and endorsement for the partnership, which supports the flagship 'Biopharma SHAKTI' initiative to build a robust biopharma ecosystem.
